A number of other brokerages also recently issued reports on GRFS. JPMorgan Chase & Co. downgraded shares of Sogou from a neutral rating to an underweight rating and cut their price objective for the stock from $5.50 to $4.12 in a research report on Thursday, June 27th. Zacks Investment Research downgraded shares of ExlService from a hold rating to a sell rating in a research report on Wednesday, July 10th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average target price of $20.75.
Shares of GRIFOLS S A/S stock opened at $21.95 on Monday. The stock has a 50 day moving average price of $20.05. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.13 and a current ratio of 2.87. GRIFOLS S A/S has a 52-week low of $17.42 and a 52-week high of $22.21. The stock has a market cap of $15.18 billion, a P/E ratio of 18.76, a P/E/G ratio of 1.29 and a beta of 1.16.
The company also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, June 18th. Stockholders of record on Monday, June 10th were given a $0.14 dividend. The ex-dividend date of this dividend was Friday, June 7th. GRIFOLS S A/S’s payout ratio is currently 22.22%.
Large investors have recently added to or reduced their stakes in the business. First Trust Advisors LP grew its position in GRIFOLS S A/S by 9.7% during the 1st quarter. First Trust Advisors LP now owns 5,125,719 shares of the biotechnology company’s stock worth $103,078,000 after purchasing an additional 453,032 shares during the last quarter. Marshall Wace LLP grew its position in GRIFOLS S A/S by 628.4% during the 1st quarter. Marshall Wace LLP now owns 133,498 shares of the biotechnology company’s stock worth $2,685,000 after purchasing an additional 115,170 shares during the last quarter. Two Sigma Advisers LP grew its position in GRIFOLS S A/S by 502.7% during the 4th quarter. Two Sigma Advisers LP now owns 134,400 shares of the biotechnology company’s stock worth $2,468,000 after purchasing an additional 112,100 shares during the last quarter. Bank of America Corp DE grew its position in GRIFOLS S A/S by 1.2% during the 4th quarter. Bank of America Corp DE now owns 1,443,713 shares of the biotechnology company’s stock worth $26,506,000 after purchasing an additional 16,818 shares during the last quarter. Finally, CIBC Asset Management Inc grew its position in GRIFOLS S A/S by 79.6% during the 1st quarter. CIBC Asset Management Inc now owns 210,981 shares of the biotechnology company’s stock worth $4,243,000 after purchasing an additional 93,510 shares during the last quarter. 19.01% of the stock is currently owned by institutional investors.
About GRIFOLS S A/S
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
Recommended Story: Why do companies issue convertible shares?
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.